Drugs & Aging

, Volume 25, Issue 12, pp 1007–1019

Sialorrhoea and Drooling in Patients with Parkinson’s Disease

Epidemiology and Management
Review Article

Abstract

Although often less recognized than motor symptoms, non-motor effects represent an important source of disability for many parkinsonian patients. Of these non-motor symptoms, sialorrhoea, defined as the inability to control oral secretions resulting in excessive saliva accumulation in the oropharynx, constitutes perhaps one of the most bothersome and troubling problems, often causing social embarrassment and isolation. In patients with Parkinson’s disease (PD), this symptom is thought to be due to restricted swallowing and dysfunction, rather than to hypersecretion of saliva. Only a few well designed studies have been conducted to determine the optimal treatment for sialorrhoea in PD. A combination of approaches appears to be necessary to obtain successful results.

References

  1. 1.
    Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson’s disease: an evidence based assessment. Lancet 2002; 359: 1589–98PubMedCrossRefGoogle Scholar
  2. 2.
    Gulati A, Forbes A, Stegie F, et al. A clinical observational study of the pattern and occurrence of non-motor symptoms in Parkinson’s disease ranging from early to advanced disease [abstract]. Mov Disord 2004; 19Suppl. 9: S406Google Scholar
  3. 3.
    Visser M, Marinus J, Stiggelbout AM, et al. Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPAAUT. Mov Disord 2004; 19: 1306–12PubMedCrossRefGoogle Scholar
  4. 4.
    Wüllner U, Schmitz-Hübsch T, Antony G, et al. Autonomic dysfunction in 3414 Parkinson’s disease patients enrolled in the German Network on Parkinson’s Disease (KNP e.V.): the effect of ageing. Eur J Neurol 2007 Dec; 14(12): 1405–8PubMedCrossRefGoogle Scholar
  5. 5.
    Lal D, Hotaling AJ. Drooling. Curr Opin Otolaryngol Head Neck Surg 2006 Dec; 14(6): 381–6PubMedCrossRefGoogle Scholar
  6. 6.
    Manor Y, Giladi N, Cohen A, et al. Validation of a swallowing disturbance questionnaire for detecting dysphagia in patients with Parkinson’s disease. Mov Disord 2007; 22: 1917–21PubMedCrossRefGoogle Scholar
  7. 7.
    Leopold NA, Kagel MC. Prepharyngeal dysphagia in Parkinson’s disease. Dysphagia 1996; 11(1): 14–22PubMedCrossRefGoogle Scholar
  8. 8.
    Nagler R, Hershkovich O. Relationships between age, drugs, oral sensorial complaints and salivary profile. Arch Oral Biol 2005; 50(1): 7–16PubMedCrossRefGoogle Scholar
  9. 9.
    Vissink A, Spijkervet FK, Van Nieuw Amerongen A. Aging and saliva: a review of the literature. Spec Care Dent 1996; 16: 95–103CrossRefGoogle Scholar
  10. 10.
    Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease: frequency and pathophysiology. Neurology 1992; 42: 726–32PubMedCrossRefGoogle Scholar
  11. 11.
    Johnston BT, Li Q, Castell JA, et al. Swallowing and esophageal function in Parkinson’s disease. Am J Gastroenterol 1995; 90: 1741–6PubMedGoogle Scholar
  12. 12.
    Bardow A, Nyvad B, Nauntofte B. Relationships between medication intake, complaints of dry mouth, salivary flow rate and composition, and the rate of tooth demineralization in situ. Arch Oral Biol 2001; 46: 413–23PubMedCrossRefGoogle Scholar
  13. 13.
    Friedman A, Potulska A. Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. Parkins Relat Disord 2001; 1: 329–32CrossRefGoogle Scholar
  14. 14.
    Korcyn AD. Autonomic nervous system dysfunction in Parkinson’s disease. In: Calne DB, Crippa D, Trabucchi M, et al., editors. Parkinsonism and aging. New York: Raven Press, 1989: 211–9Google Scholar
  15. 15.
    Martignoni E, Pacchetti C, Godi L, et al. Autonomic disorders in Parkinson’s disease. J Neural Transm 1995 Suppl. 45: 11–19Google Scholar
  16. 16.
    Pfeiffer RF, Quigley MM. Gastrointestinal motility problems in patients with Parkinson’s disease. CNS Drugs 1999; 11: 436–48CrossRefGoogle Scholar
  17. 17.
    Edwards LL, Quigley EM, Harned RK, et al. Characterization of swallowing and defecation in Parkinson’s disease. Am J Gastroenterol 1994; 89: 15–25PubMedGoogle Scholar
  18. 18.
    Bagheri H, Damase-Michel C, Lapeyre-Mestre M, et al. A study of salivary secretion in Parkinson’s disease. Clin Neuropharmacol 1999: 22; 213–215PubMedGoogle Scholar
  19. 19.
    Bateson MC, Gibberd FB, Wilson RS. Salivary symptoms in Parkinson disease. Arch Neurol 1973; 29(4): 274–5PubMedCrossRefGoogle Scholar
  20. 20.
    Ali G, Wallace K, Schwartz R, et al. Mechanisms of oralpharyngeal dysphagia in patients with Parkinson’s disease. Gastroenterology 1996; 110: 383–92PubMedCrossRefGoogle Scholar
  21. 21.
    Kalf JG, Smit AM, Bloem BR, et al. Impact of drooling in Parkinson’s disease. J Neurol 2007 Sep; 254(9): 1227–32PubMedCrossRefGoogle Scholar
  22. 22.
    Chou KL, Evatt M, Hinson V, et al. Sialorrhea in Parkinson’s disease: a review. Mov Disord 2007; 22: 2306–13PubMedCrossRefGoogle Scholar
  23. 23.
    Bagheri H, Damase-Michel C, Lapeyre-Mestre M, et al. A study of salivary secretion in Parkinson’s disease. Clin Neuropharmacol 1999; 22: 213–5PubMedGoogle Scholar
  24. 24.
    Parkinson J. An essay on the shaking palsy. J Neuropsychiatry Clin Neurosci 2002; 14: 223–36PubMedCrossRefGoogle Scholar
  25. 25.
    Edwards LL, Pfeiffer RF, Quigley EM, et al. Gastrointestinal symptoms in Parkinson’s disease. Mov Disord 1991; 6(2): 151–6PubMedCrossRefGoogle Scholar
  26. 26.
    Eadie MJ, Tyrer JH. Alimentary disorder in Parkinsonism. Australas Ann Med 1965; 14: 13–22PubMedGoogle Scholar
  27. 27.
    Edgar WM. Saliva: its secretion, composition and functions. Br Dent J 1992; 172: 305–12PubMedCrossRefGoogle Scholar
  28. 28.
    Humphrey SP, Williamson RT. A review of saliva: normal composition, flow, and function. J Prosthet Dent 2001 Feb; 85(2): 162–9PubMedCrossRefGoogle Scholar
  29. 29.
    Takayanagi A, Nomura T, Yamanaka S, et al. A modified device for long term sampling of parotid saliva in various experimental conditions. Bull Tokyo Dent Coll 1995; 36: 69–73PubMedGoogle Scholar
  30. 30.
    Ghezzi EM, Lange LA, Ship JA. Determination of variation of stimulated salivary flow rates. J Dent Res 2000; 79: 1874–8PubMedCrossRefGoogle Scholar
  31. 31.
    Dodds WJ. The physiology of swallowing. Dysphagia 1989: 3: 171–8PubMedCrossRefGoogle Scholar
  32. 32.
    Rothstein RD. A systematic approach to a patient with dysphagia. Hosp Pract 1997; 32: 169–75Google Scholar
  33. 33.
    Ertekin C, Tarlaci S, Aydogdu I, et al. Electrophysiological evaluation of pharyngeal phase of swallowing in patients with Parkinson’s disease. Mov Disord 2002; 17: 942–9PubMedCrossRefGoogle Scholar
  34. 34.
    Marg S, Walz B, Blenau W. The effects of dopamine receptor agonists and antagonists on the secretory rate of cockroach (Periplaneta americana) salivary glands. J Insect Physiol 2004; 50: 821–30PubMedCrossRefGoogle Scholar
  35. 35.
    Koga T, Kobashi M, Mizutani M, et al. Area postrema mediates gastric motor response induced by apomorphine in rats. Brain Res 2003; 960: 122–31PubMedCrossRefGoogle Scholar
  36. 36.
    Pazo JH, Belferte JE. Basal ganglia and functions of the autonomic nervous system. Cell Mol Neurobiol 2002; 22: 645–54PubMedCrossRefGoogle Scholar
  37. 37.
    Pazo JH, Medina J, Tumilasci O. The role of the caudateputamen nucleus in salivary secretion induced by L-dopa. Neuropharmacology 1982; 21: 261–5PubMedCrossRefGoogle Scholar
  38. 38.
    Spivak B, Adlersberg S, Rosen L, et al. Trihexyphenidyl treatment of clozapine-induced hypersalivation. Int Clin Psychopharmacol 1997; 12: 213–5PubMedCrossRefGoogle Scholar
  39. 39.
    Penttilä J, Syvälahti E, Hinkka S, et al. The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system: a randomized placebo-controlled study on healthy volunteers. Psychopharmacology (Berl) 2001 Apr; 154(4): 343–9CrossRefGoogle Scholar
  40. 40.
    Crosby N, Deane KH, Clarke CE. Amantadine in Parkinson’s disease. Cochrane Database Syst Rev 2003; (1): CD003468Google Scholar
  41. 41.
    Proulx M, de Courval FP, Wiseman MA, et al. Salivary production in Parkinson’s disease. Mov Disord 2005; 20: 204–7PubMedCrossRefGoogle Scholar
  42. 42.
    Persson M, Osterberg T, Granérus AK, et al. Influence of Parkinson’s disease on oral health. Acta Odontol Scand 1992; 50: 37–42PubMedCrossRefGoogle Scholar
  43. 43.
    Sockalingam S, Shammi C, Remington G. Clozapine-induced hypersalivation: a review of treatment strategies. Can J Psychiatry 2007; 52: 377–84PubMedGoogle Scholar
  44. 44.
    Hori T, Makabe K, Nemoto K, et al. Hypersalivation induced by olanzapine with fluvoxamine. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 758–60PubMedCrossRefGoogle Scholar
  45. 45.
    Donaldson SR. Sialorrhea as a side effect of lithium: a case report. Am J Psychiatry 1982; 139: 1350–1PubMedGoogle Scholar
  46. 46.
    Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol 1982 Jan; 11(1): 41–7PubMedCrossRefGoogle Scholar
  47. 47.
    Müller T, Welnic J, Fuchs G, et al. The DONPAD study: treatment of dementia in patients with Parkinson’s disease with donepezil. J Neural Transm Suppl 2006; 71: 27–30PubMedCrossRefGoogle Scholar
  48. 48.
    Freudenreich O, Herz L, Deckersbach T, et al. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology 2005; 181: 358–63PubMedCrossRefGoogle Scholar
  49. 49.
    Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord 2005; 20Suppl. 11: S11–6PubMedCrossRefGoogle Scholar
  50. 50.
    Santens P, de Noordhout AM, Belgian EODWO Study Group. Detection of motor and non-motor symptoms of end-of dose wearing-off in Parkinson’s disease using a dedicated questionnaire: a Belgian multicenter survey. Acta Neurol Belg 2006 Sep; 106(3): 137–41PubMedGoogle Scholar
  51. 51.
    Merello MJ, Leiguarda RC. Adynamic bowel syndrome with dramatic response to apomorphine. Clin Neuropharmacol 1994; 17: 574–8CrossRefGoogle Scholar
  52. 52.
    Chauncey HH, Feller RP, Kapur KK. Longitudinal age-related changes in human parotid saliva composition. J Dent Res 1987; 66: 599–602PubMedCrossRefGoogle Scholar
  53. 53.
    Tumilasci OR, Cersosimo MG, Belferte JE, et al. Quantitative study of salivary secretion in Parkinson’s disease. Mov Disord 2006; 21: 660–7PubMedCrossRefGoogle Scholar
  54. 54.
    Aung W, Murata Y, Ishida R, et al. Study of quantitative oral radioactivity in salivary gland scintigraphy and determination of the clinical stage of Sjogren’s syndrome. J Nucl Med 2001; 42: 38–43PubMedGoogle Scholar
  55. 55.
    Pai S, Ghezzi E, Ship J, et al. Development of a visual analogue scale questionnaire for subjective assessment of salivary dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91: 311–6PubMedCrossRefGoogle Scholar
  56. 56.
    White KD. Salivation: a review and experimental investigation of major techniques. Psychophysiology 1977; 14: 203–12PubMedCrossRefGoogle Scholar
  57. 57.
    Jones JM, Watkins CA, Hand JS, et al. Comparison of three salivary flow rate assessment methods in an elderly population. Community Dent Oral Epidemiol 2000; 28: 177–84PubMedCrossRefGoogle Scholar
  58. 58.
    Jongerius PH, van Limbeek J, Rotteveel JJ. Assessment of salivary flow rate: biologic variation and measure error. Laryngoscope 2004; 114: 1801–4PubMedCrossRefGoogle Scholar
  59. 59.
    Ramaker C, Marinus J, Stiggelbout AM, et al. Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord 2002; 17(5): 867–76PubMedCrossRefGoogle Scholar
  60. 60.
    Marks L, Turner K, O’Sullivan J, et al. Drooling in Parkinson’s disease: a novel speech and language therapy intervention. Int J Lang Commun Disord 2001; 36 Suppl.: 282–7PubMedCrossRefGoogle Scholar
  61. 61.
    Thomas-Stonell N, Greenberg J. Three treatment approaches and clinical factors in the reduction of drooling. Dysphagia 1988; 3(2): 73–8PubMedCrossRefGoogle Scholar
  62. 62.
    Perez Lloret S, Piran Arce G, Rossi M, et al. Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson’s disease. Mov Disord 2007; 22: 107–11PubMedCrossRefGoogle Scholar
  63. 63.
    Jongerius PH, van Tiel P, van Limbeek J, et al. A systematic review for evidence of efficacy of anticholinergic drugs to treat drooling. Arch Dis Child 2003 Oct; 88(10): 911–4PubMedCrossRefGoogle Scholar
  64. 64.
    Camp-Bruno JA, Winsberg BG, Green-Parsons AR, et al. Efficacy of benztropine therapy for drooling. Dev Med Child Neurol 1989; 31: 309–19PubMedCrossRefGoogle Scholar
  65. 65.
    Gillis MC, ed. Robinul product monograph. In: Compendium of Pharmaceuticals and specialties. Toronto (ON): Canadian Pharmacists Association, 1999: 1578–9Google Scholar
  66. 66.
    Blasco PA, Stansbury JCK. Glycopyrrolate treatment of chronic drooling. Arch Pediatr Adolesc Med 1996; 150: 932–5PubMedCrossRefGoogle Scholar
  67. 67.
    Blasco PA. Management of drooling: 10 years after the Consortium on Drooling, 1990. Dev Med Child Neurol 2002 Nov; 44(11): 778–81PubMedCrossRefGoogle Scholar
  68. 68.
    Fox S, Thomsen T, Asante A, et al. Ipratropium bromide spray as a treatment of sialorrhea in Parkinson’s disease [abstract]. Mov Disorders 2006; 21Suppl. 15: S573Google Scholar
  69. 69.
    Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 2002; 17(6): 1318–20PubMedCrossRefGoogle Scholar
  70. 70.
    Heine RG, Catto-Smith AG, Reddihough DS. Effect of antireflux medication on salivary drooling in children with cerebral palsy. Dev Med Child Neurol 1996; 38: 1030–6PubMedCrossRefGoogle Scholar
  71. 71.
    Newall AR, Orser R, Hunt M. The control of oral secretions in bulbar ALS/MND. J Neurol Sci 1996; 139 Suppl.: 43–4PubMedCrossRefGoogle Scholar
  72. 72.
    Grabowski J. Clonidine treatment of clozapine-induced hypersalivation. J Clin Psychopharmacol 1992; 12(1): 69–70PubMedCrossRefGoogle Scholar
  73. 73.
    Webber MA, Szwast SJ, Steadman TM, et al. Guanfacine treatment of Clozapine induced sialorrhea. J Clin Psychopharmacol 2004; 24(6): 675–6PubMedCrossRefGoogle Scholar
  74. 74.
    Kushnir M, Eilam A, Heldman E. Modafinil reduces drooling in Parkinson’s disease. Mov Disord 2006; 21Suppl. 15: S598–9Google Scholar
  75. 75.
    Bushara KO. Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment — botulinum toxin A injections of the parotid glands. Med Hypotheses 1997; 48: 337–9PubMedCrossRefGoogle Scholar
  76. 76.
    Dogu O, Apaydin D, Sevim S, et al. Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease. Clin Neurol Neurosurg 2004; 106: 93–6PubMedCrossRefGoogle Scholar
  77. 77.
    Lagalla G, Millevolte M, Capecci M, et al. Botulinum toxin type A for drooling in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2006; 21: 704–7PubMedCrossRefGoogle Scholar
  78. 78.
    Lipp A, Trottenberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003; 61: 1279–81PubMedCrossRefGoogle Scholar
  79. 79.
    Mancini F, Zangaglia R, Cristina S, et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 2003; 18: 685–8PubMedCrossRefGoogle Scholar
  80. 80.
    Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology 2004; 62: 37–40PubMedCrossRefGoogle Scholar
  81. 81.
    Molloy L. Treatment of sialorrhea in patients with Parkinson’s disease: best current evidence. Curr Opin Neurol 2007; 20: 493–8PubMedCrossRefGoogle Scholar
  82. 82.
    Andersen PM, Gronberg H, Franzen L, et al. External radiation of the parotid glands significantly reduces drooling in patients with motor neurone disease with bulbar paresis. J Neurol Sci 2001; 191: 111–4PubMedCrossRefGoogle Scholar
  83. 83.
    Stalpers LJ, Moser EC. Results of radiotherapy for drooling in amyotrophic lateral sclerosis. Neurology 2002; 58: 1308PubMedCrossRefGoogle Scholar
  84. 84.
    Borg M, Hirst F. The role of radiation therapy in the management of sialorrhea. Int J Radiat Oncol Biol Phys 1998; 41: 1113–9PubMedCrossRefGoogle Scholar
  85. 85.
    Schneider AB, Lubin J, Ron E, et al. Salivary gland tumors after childhood radiation treatment for benign conditions of the head and neck: dose-response relationships. Radiat Res 1998; 149: 625–30PubMedCrossRefGoogle Scholar
  86. 86.
    Shigematsu H, Magoshi S, Suzuki S, et al. An apparent radiation-induced carcinoma of the parotid gland following treatment for adenoid cystic carcinoma of the sublingual gland: a case report. J Oral Maxillofac Surg 2004; 62: 1169–74PubMedCrossRefGoogle Scholar
  87. 87.
    Ward MJ, Levine PA. Salivary gland tumors. In: Close LG, Larson DL, Shah JP, editors. Essentials of head and neck oncology. New York: Thieme, 1998Google Scholar
  88. 88.
    Postma AG, Heesters M, van Laar T. Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism. Mov Disorders 2007: 22; 2430–5CrossRefGoogle Scholar
  89. 89.
    Limbrock GJ, Fischer-Brandies H, Avalle C. Castillo-Morales’ orofacial therapy: treatment of 67 children with Down syndrome. Dev Med Child Neurol 1991; 33(4): 296–303PubMedCrossRefGoogle Scholar
  90. 90.
    Crysdale WS, McCann C, Roske L, et al. Saliva control issues in the neurologically challenged: a 30 year experience in team management. Int J Pediatr Otorhinolaryngol 2006; 70(3): 519–27PubMedCrossRefGoogle Scholar
  91. 91.
    Marks L, Turner K, O’Sullivan J, et al. Drooling in Parkinson’s disease: a novel speech and language therapy intervention. Int J Lang Commun Disord 2001; 36 Suppl.: 282–7PubMedCrossRefGoogle Scholar
  92. 92.
    Meningaud JP, Pitak-Arnnop P, Chikhani L, et al. Drooling of saliva: a review of the etiology and management options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101: 48–57PubMedCrossRefGoogle Scholar
  93. 93.
    Grewal DS, Hiranandani NL, Rangwalla ZA, et al. Transtympanic neurectomies for control of drooling. Auris Nasus Larynx 1984; 11(2): 109–14PubMedGoogle Scholar
  94. 94.
    Mullins WM, Gross CW, Moore JM. Long-term follow-up of tympanic neurectomy for sialorrhea. Laryngoscope 1979; 89(8): 1219–23PubMedGoogle Scholar
  95. 95.
    Brundage SR, Moore WD. Submandibular gland resecton and bilateral parotid duct ligation as a management for chronic drooling in cerebral palsy. Plast Reconstr Surg 1989 Mar; 83(3): 443–6PubMedCrossRefGoogle Scholar
  96. 96.
    Becmeur F, Horta-Geraud P, Brunot B, et al. Diversion of salivary flow to treat drooling in patients with cerebral palsy. J Pediatr Surg 1996 Dec; 31(12): 1629–33PubMedCrossRefGoogle Scholar
  97. 97.
    Hamani C, Neimat J, Lozano AM. Deep brain stimulation for the treatment of Parkinson’s disease. J Neural Transm Suppl. 2006; 70: 393–9PubMedCrossRefGoogle Scholar
  98. 98.
    Merello M, Starkstein S, Nouzeilles MI, et al. Bilateral pallidotomy for treatment of Parkinson’s disease induced corticobulbar syndrome and psychic akinesia avoidable by globus pallidus lesion combined with contralateral stimulation. J Neurol Neurosurg Psychiatry 2001; 71: 611–4PubMedCrossRefGoogle Scholar
  99. 99.
    Ghika J, Ghika-Schmid F, Fankhauser H, et al. Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson’s disease: neuropsychological and neurological side effects: report of four cases and review of the literature. J Neurosurg 1999; 91: 313–21PubMedCrossRefGoogle Scholar
  100. 100.
    Merello M. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. In: Tarsy D, Okun M, Vitek J, et al., eds. Deep brain stimulation in neurological and psychiatric disorders. Totowa (NJ): Humana Press; 2008: 253–76CrossRefGoogle Scholar
  101. 101.
    Serrano-Dueñas M. Sialorrhea in patients with Parkinson: a six year prospective study. Rev Neurol 2003; 37: 623–6PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Neuroscience DepartmentRaul Carrea Institute for Neurological Research (FLENI)Buenos AiresArgentina

Personalised recommendations